Owlstone Medical has announced agreements with Functional Gut Clinic and Functional Gut Diagnostics. The partnership aims to strengthen the provision of efficient and high-quality at-home breath testing through a UK Lab Services Agreement and accelerate the development of future breath tests in digestive health through a Collaboration Agreement.

Memo Therapeutics AG has announced that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

Sphere Fluidics has announced it has enhanced the capability and performance of its Cyto-Mine® System. The simplified design offers improved functionality to help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.

The Coalition for Epidemic Preparedness Innovations, or CEPI, will expand its centralized laboratory network, a global initiative to harmonize the assessment of COVID-19 vaccine candidates undergoing testing, to also evaluate clinical trial samples against priority Variants of Concern.

PerkinElmer, Inc. has announced that it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is expected to close during the second quarter of 2021.

Bio-Rad Laboratories, Inc. has announced the launch of the SEQuoia RiboDepletion Kit, which improves assay efficiency by eliminating irrelevant ribosomal RNA (rRNA) fragments from an RNA-Seq library.

ERS Genomics Limited and GenScript Biotech Corporation have announced a non-exclusive license agreement granting GenScript access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

Research findings show that annual PM2.5 concentrations in some African cities are as much as 5 times over the WHO limit for health-harmful concentration. Findings like these place air pollution as the leading cause of premature death in Africa, overtaking AIDs related deaths.

FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing cell culture media products and services.

Oxford Immunotec has announced that its T-SPOT®.COVID test will be used for T cell testing in the COV-AD (COVID infection in patients with Antibody Deficiency) study in collaboration with the University of Birmingham.